BZ371A Pipeline

Another Day Pharma (ADP) continues the pioneering work of Biozeus, developing BZ371A from a peptide originally derived from the venom of the Brazilian wandering spider into a safe, synthetic, topical therapy.

In men, Phase II trials showed efficacy after prostate surgery, both alone and in combination with tadalafil. In women, BZ371A achieved the first convincing efficacy in premenopausal sexual arousal disorder, alongside strong results in postmenopausal patients.

With its unique non-hormonal, locally acting mechanism, ADP's pipeline reflects years of progress. The next step is to advance BZ371A into Phase III, aiming to deliver the first safe and effective treatment for both male and female sexual dysfunction.

Medical laboratory

Parallel Development Programs

Independent but synchronized clinical trials for men and women

Men's Health Track

Phase III

Planned

• PDEi Resistant ED

• Contraindicated PDE5i

• Post-Prostatectomy

  • Approximately 100 subjects
  • Three parallel studies

Phase II

Completed April 2025

• Post-Prostatectomy ED

  • 74 participants enrolled
  • 10× improvement in combination therapy
  • No serious adverse events
View Full Results →

Phase I

Completed

  • Safety & tolerability established
  • Optimal dosing determined
  • Pharmacokinetics characterized
Women's Health Track

Phase III

Planned

• Pre-Menopausal Women

• Post-Menopausal Women

  • Approximately 300 subjects
  • Two parallel studies

Phase II

Completed May 2025

• Sexual Arousal Disorder

  • 30 women randomized
  • 86% arousal satisfaction vs 56% placebo
  • Outstanding safety profile
View Full Results →

Phase I

Completed

  • Safety profile confirmed
  • Topical formulation optimized
  • Initial efficacy signals observed

Outstanding Phase II Results for Men

BZ371A demonstrated compelling efficacy in a Phase II clinical trial targeting erectile dysfunction in men recovering from radical prostatectomy. The study enrolled 74 participants.

10×

Improvement in combination therapy

0

Serious adverse events*

Improvements were measured by the International Index of Erectile Function (IIEF-5), showing statistically and clinically meaningful gains for patients with nerve damage following prostate surgery.

View full results →

Outstanding Phase II Results for Women

BZ371A achieved breakthrough results in Female Sexual Interest/Arousal Disorder (FSIAD), marking the first convincing efficacy in premenopausal women. The study enrolled 30 women.

86%

Arousal satisfaction vs 56% placebo

0

Serious adverse events*

Assessed using the Female Sexual Function Index (FSFI), BZ371A showed significant improvements in arousal, lubrication, orgasm, satisfaction, and pain reduction in both pre- and postmenopausal women.

View full results →

*Safety Profile: No serious adverse events (SAEs) were reported in any of the clinical trials (Phase I or Phase II, male or female). Only mild, transient events were observed, consistent with good safety and tolerability.